4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
5 citations
,
January 2010 in “The Journal of Internal Korean Medicine” Lygodium japonicum may help treat benign prostatic hyperplasia.
January 2025 in “Dusunen Adam The Journal of Psychiatry and Neurological Sciences” 20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
January 2025 in “Biomedical Engineering Letters” MXD@CP could be a promising new topical treatment for hair loss.
1 citations
,
May 2021 in “Scientific Reports” Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
January 2025 in “International Journal of Scientific Research in Science and Technology” The method is effective and suitable for testing finasteride tablets.
80 citations
,
August 1991 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
1 citations
,
June 2022 in “JCRPE” Metreleptin treatment significantly improved metabolic health in a boy with congenital generalized lipodystrophy.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
3 citations
,
October 1993 in “Endocrinology” September 2004 in “Inpharma Weekly” 2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
16 citations
,
November 2023 in “Scientific Reports” The niosomes effectively target hair follicles for acne treatment.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
75 citations
,
March 1999 in “Fertility and sterility” Finasteride, CPA, and flutamide are all equally effective in reducing excessive hair growth in women.
September 2011 in “Urology” Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
December 2023 in “Natural product research” Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.